Stonebridge Biopharma plc (SBBP) is nearing its transformational value inflection point with the expected release of Recorlev's Phase 3 topline data for Cushing's disease due next month (September 2020). If Recorlev's Phase 3 topline data is good enough, SBBP will file a NDA in Q1 2021 with hopefully FDA approval 10 months later. This is Recorlev's second Phase 3 trial. If approved in December 2021, there would then be 2 roadmaps to material shareholder valuation gains from SBBP's Recorlev asset. Valuation gains could come from the sale of Recorlev to a Big Pharma